Abstract
Dihydrofolate reductase (DHFR) has been used successfully as a drug target in the area of anti-bacterial, anti-cancer and anti-malarial therapy. It also acts as a drug target for Leishmaniasis. Inhibition of DHFR leads to cell death through lack of thymine (nucleotide metabolism). Although the crystal structures of Leishmania major and Trypanosoma cruzi DHFR-thymidylate synthase (TS) have been resolved, to date there is no three-dimensional (3D)-structural information on DHFR-TS of Leishmania donovani chagasi, which causes visceral leishmaniasis. Our aim in this study was to model the 3D structure of L. donovani chagasi DHFR-TS, and to investigate the structural requirements for its inhibition. In this paper we describe a highly refined homology model of L. donovani chagasi DHFR-TS based on available crystallographic structures by using the Homology module of Insight II. Structural refinement and minimization of the generated L. donovani chagasi DHFR-TS model employed the Discover 3 module of Insight II and molecular dynamic simulations. The model was further validated through use of the PROCHECK, Verify_3D, PROSA, PSQS and ERRAT programs, which confirm that the model is reliable. Superimposition of the model structure with the templates L. major A chain, L. major B chain And T. cruzi A chain showed root mean square deviations of 0.69 Å, 0.71 Å and 1.11 Å, respectively. Docking analysis of the L. donovani chagasi DHFR-TS model with methotrexate enabled us to identify specific residues, viz. Val156, Val30, Lys95, Lys75 and Arg97, within the L. donovani chagasi DHFR-TS binding pocket, that play an important role in ligand or substrate binding. Docking studies clearly indicated that these five residues are important determinants for binding as they have strong hydrogen bonding interactions with the ligand.
Similar content being viewed by others
References
Cunha AM, Chagas E (1937) New species of protozoa of the genus Leishmania pathogenic to man Leishmania chagasi n. sp previous note. O Hospital 11:3–9
Croft SL, Coombs GH (2003) Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19:502–508. doi:10.1016/j.pt.2003.09.008
Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft Sl, Desjeux P, Wasunna MK, Bryceson ADM (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2:494–501. doi:10.1016/S1473-3099(02)00347-X
Davies CR, Kaye P, Croft SL, Sunder S (2003) Leishmaniasis: new approaches to disease control. BMJ 326:377–382. doi:10.1136/bmj.326.7385.377
Desjeux P (2001) Worldwide increasing risk factors for leishmaniasis. Med Microbiol Immunol 190:77–79. doi:10.1007/s004300100085
World Health Organization (2000) The Leishmaniasis and Leishmania/HIV co-infections. Fact Sheet Number 116. WHO, Geneva, Switzerland
Shafinaz FC, Villamor VB, Guerrero RH, Leal I, Brun R, Croft SL, Goodman JM, Maes L, Ruiz-Perez LM, Pacanowska DG, Gilbert IH (1999) Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase. J Med Chem 42:4300–4312. doi:10.1021/jm981130+
Decampo R (2001) Recent developments in the chemotherapy of Cha-gas’ disease. Curr Pharm Des 7:1157–1164. doi:10.2174/1381612013397546
McLuskey K, Gibellini F, Carvalho P, Avery MA, Huntera WN (2004) Inhibition of Leishmania major pteridine reductase by 2, 4, 6-triaminoquinazoline: structure of the NADPH ternary complex. Acta Cryst 60:1780–1785. doi:10.1107/S0907444904018955
Ferone R, Roland S (1980) Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata. Proc Natl Acad Sci USA 77:5802–5806
Garrett CE, Coderre JA, Meek TD, Garvey EP, Claman DM, Beverly SM, Santhi DV (1984) A Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa. Mol Biochem Parasitol 11:257–265. doi:10.1016/0166-6851(84)90070-7
Ivanetich KM, Santhi DV (1990) Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa. FASEB J 4:1591–1597. doi:0892-6638/90/0004-1591/$O1.50
Bermingham A, Derrick JP (2002) The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. BioEssays 24:637–648. doi:10.1002/bies.10114
Walsh C (2003) Antibiotics: actions, origins, resistance. ASM, Washington. doi:10.1110/ps.041032204
Then RL (2004) Antimicrobial dihydrofolate reductase inhibitors-achievements and future options: review. J Chemother 16:3–12
Zheng QC, Li ZS, Sun M, Zhang Y, Sun CC (2005) Homology modeling and substrate binding study of nudix hydrolase Ndx1 from Thermos thermophilus HB8. Biochem Biophys Res Commun 333:881–887
Xu W, Cai P, Yan M, Xu L, Ouyang PK (2007) Molecular docking of xylitol and xylose isomerase from Thermus thermophilus and model analysis. Chem J Chin Univ 28:971–973
He YP, Hu HR, Xu LS (2005) Structure–activity relationship studies on 6-naphthylmethyl substituted HEPT derivatives as nonnucleoside reverse transcriptase inhibitors based on molecular docking. Chem J Chin Univ 26:254–258
Knighton DR, Kan CC, Howland E, Janson CA, Hostomska Z, Welsh KM, Matthews DA (1994) Structure of and kinetic channelling in bifunctional dihydrofolate reductase-thymidylate synthase. Nat Struct Biol 1:186–194. doi:10.1038/nsb0394-186
Senkovich O, Schormann N, Chattopadhyay D (2009) Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate. Acta Cryst 65:704–716. doi:10.1107/S090744490901230X
InsightII (2007) Accelrys, San Diego
GOLD (2006) CCDC, Cambridge
Needleman SB, Wunsch CD (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 48:443–453. doi:10.1016/0022-2836(70)90057-4
Jaroszewski L, Pawlowski K, Godzik A (1998) Multiple model approach: exploring the limits of comparative modeling. J Mol Model 4:294–309. doi:10.1007/s008940050087
Luthy R, Bowie JU, Eisenberg D (1992) Assessment of protein models with three-dimensional profiles. Nature 356:83–85. doi:10.1038/356083a0
Colovos C, Yeates TO (1993) Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 2:1511–1519. doi:10.1002/pro.5560020916
Hooft RWW, Vriend G, Sander C, Abola EE (1996) Errors in protein structures. Nature 381:272–272. doi:10.1038/381272a0
Sippl MJ (1993) Boltzmann’s principle, knowledge-based mean fields and protein folding. J Comput Aided Mol Des 7:473–501. doi:10.1007/BF02337562
Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993) PROCHECK a program to check the stereo chemical quality of protein structure. J Appl Cryst 26:283–291. doi:10.1107/S0021889892009944
Guex N, Peitsch MC (1997) SWISS MODEL and the Swiss pdb viewer: an environment for comparative protein modeling. Electrophoresis 18:2714–2723. doi:10.1093/nar/gkg520
Cerius2 (2006) Accelrys, San Diego
Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein–ligand interactions. Protein Eng 8:127–134. doi:10.1093/protein/8.2.127
Acknowledgments
The authors thank the Council for Scientific and Industrial Research (CSIR), New Delhi, India, for providing financial assistance from a grant under Mission Mode Program CMM 0017. We thank Prof. David A. Matthews, Agouron Pharmaceuticals, San Diego, CA, for providing the coordinates of the Leishmania major crystallographic structure. L.M. and P.M. thank CSIR, New Delhi, India, for Project Assistantship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maganti, L., Manoharan, P. & Ghoshal, N. Probing the structure of Leishmania donovani chagasi DHFR-TS: comparative protein modeling and protein–ligand interaction studies. J Mol Model 16, 1539–1547 (2010). https://doi.org/10.1007/s00894-010-0649-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-010-0649-0